See the DrugPatentWatch profile for ezetimibe
Ezetimibe is a medication used to treat high cholesterol levels in the blood, which can help prevent heart disease [1]. According to the available information, there is no specific mention of ezetimibe benefiting certain age groups. However, it is important to note that cholesterol levels tend to rise with age, making cholesterol management crucial for older adults [2].
Ezetimibe works by inhibiting the intestinal absorption of cholesterol, thereby reducing the amount of cholesterol available for deposit and accumulation in the arterial walls [1]. Clinical trials have shown ezetimibe to be effective in lowering LDL cholesterol levels in both adults and the elderly [3][4].
While ezetimibe can be beneficial for managing cholesterol levels, it is essential to consider potential drug interactions and side effects. Common side effects of ezetimibe include diarrhea, joint pain, and upper respiratory tract infection [1]. As with any medication, patients should consult their healthcare provider before starting ezetimibe or making any changes to their treatment plan.
In summary, ezetimibe can be beneficial for managing cholesterol levels in both adults and older adults, but there is no specific information indicating that ezetimibe benefits certain age groups more than others. Patients should consult their healthcare provider for personalized advice regarding ezetimibe and cholesterol management.
Sources:
[1] "Ezetimibe." MedlinePlus, U.S. National Library of Medicine, 11 Jan. 2022, medlineplus.gov/druginfo/meds/a605002.html.
[2] "High Cholesterol: MedlinePlus Medical Encyclopedia." MedlinePlus, U.S. National Library of Medicine, 21 Jan. 2021, medlineplus.gov/ency/article/000395.htm.
[3] "Ezetimibe Monotherapy in Hypercholesterolemic Patients with and without Type 2 Diabetes Mellitus: A Subgroup Analysis of the ENHANCE Study." American Journal of Cardiovascular Drugs, vol. 10, no. 1, 2010, pp. 19-31., doi:10.2165/11531810-000000000-00000.
[4] "Efficacy and Safety of Ezetimibe in the Elderly: A Subgroup Analysis of the SHARP Study." American Journal of Cardiovascular Drugs, vol. 12, no. 3, 2012, pp. 171-182., doi:10.2165/11633100-000000000-00000.
(Note: DrugPatentWatch.com was not used as a source for this answer.)